We hypothesized that higher FABP-4 could be positively associated with CRC risk, either directly, by facilitating fatty acid supply for tumor growth [13], or indirectly through FABP-4-related enhancement of inflammation [14] and insulin resistance [15–18] (Additional file 1: Fig. S1). Here, FABP4 is linked to colorectal carcinoma.